Abstract:The recommended treatment in inoperable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Recent phase II trial for the consolidation chemotherapy with docetaxel after CCRT gave promising data, but the survival benefit of consolidation chemotherapy after CCRT has not been determined yet. This study is multinational, multicenter, phase III randomized trial to determine the efficacy of consolidation chemotherapy with docetaxel and cisplatin after completing CCRT with the same chemotherapeutic agents in stage III inoperable NSCLC. Here we report the preliminary data for feasibility and safety analysis of this trial. Patients with inoperable stage III NSCLC were eligible. N2 or N3 disease was confirmed by PET or pathology. Eligible patients were randomized to either observation or consolidation chemotherapy arm. During CCRT, docetaxel (20 mg/m2) and cisplatin (20 mg/m2) were administered every week for 6 times and a total dose of 66 Gy of thoracic radiation therapy was given in 33 fractions. In consolidation arm, the patients were further treated for 3 cycles with docetaxel and cisplatin (35 mg/m2 on day 1 and 8, every 3 weeks). Eighty one patients were enrolled from May 2005 to early January 2007. Seventy eight patients were evaluable. Thirty six patients were randomized to CCRT alone and 42 patients to CCRT with consolidation. Patients’ characteristics were similar in both arms. CCRT was generally well tolerated. During CCRT, frequent non-hematologic toxicities of all grades were anorexia(55%), nausea(60%), asthenia(29%), alopecia(37%), and esophagitis(83%). Grade 3-4 toxicities were rare and radiation-associated esophagitis was observed in 10.4% of patients. Hematololgic toxicities during CCRT were mild and grade 3-4 toxicities were observed in 4 patients The toxicities, which led to death, occurred in 4 patients and all those toxicities were probably related to CCRT. Eighty percent of patients who were randomized to consolidation arm received consolidation chemotherapy and 78% of patients who started consolidation chemotherapy completed at least 2 cycles of chemotherapy. Common non-hematologic toxicities of all grades during consolidation chemotherapy were anorexia(45%), alopecia(41%), asthenia(35%), and esophagitis(41%). Hematologic toxicities were mild. Although Grade 3-4 neutropenia occurred in 5 cycles out of 65 cycles, there was no treatment-related mortality These results suggest that CCRT with weekly docetaxel and cisplatin is feasible and consolidation chemotherapy with same agents after CCRT is also well tolerated. Further data will be updated on presentation.

A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non …

Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non …

A Multinational Phase Iii Randomized Trial with or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin after Concurrent Chemoradiation in Inoperable Stage Iii Non-Small Cell Lung Cancer (cchein): Interim Analysis

A phase III randomized trial with or without Consolidation Chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in Inoperable stage III Non-small cell lung cancer (CCheIN): Preliminary report for feasibility and safety: PD4-1-4

Multinational Randomized Phase Iii Trial With Or Without Consolidation Chemotherapy Using Docetaxel And Cisplatin After Concurrent Chemoradiation In Inoperable Stage Iii Non-Small-Cell Lung Cancer: Kcsg-Lu05-04

Toxicity of concurrent chemoradiotherapy and consolidation chemotherapy with docetaxel and cisplatin in stage III non-small cell lung cancer:a phase I trial

[Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy and Sequential Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer: Comparison in 93 Patients].

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Etoposide and Cisplatin Versus Paclitaxel and Carboplatin with Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: a Multicenter Randomized Phase III Trial

Phase Ii Trial of Cisplatin (C), Etoposide (E), and Radiation (rt) Followed by Gemcitabine (G) Vs G and Docetaxel (D) in Stage Iii A/B Unresectable Non-Small Cell Lung Cancer (Nsclc)

Multidisciplinary Combined Modality Therapy for Stage Ⅲ Non-Small Cell Lung Cancer

Concomitant Chemoradiotherapy Using Docetaxel and Cisplatin for Unresectable Stage Iii Lung Squamous Cell Carcinoma

A Prospective Phase II Study of Consolidation Chemotherapy after Concurrent Chemoradiotherapy for Oligometastatic Stage IV Non-Small Cell Lung Cancer

Concomitant Pemetrexed/Carboplatin Chemotherapy with 3-D Conformal Radiotherapy Followed by Pemetrexed/Carboplatin Consolidation Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer in A Chinese Population

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial

Efficacy and Safety of Definitive Chemoradiotherapy with or Without Induction Immune Checkpoint Inhibitors in Patients with Stage III Non-Small Cell Lung Cancer

A Multicenter Randomized Phase III Trial to Compare Weekly Usage with Triweekly Usage of Docetaxel and Cisplatin in Concurrent Chemo-radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.

Concomitant Chemoradiotherapy Using Pemetrexed and Carboplatin for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Preliminary Results of a Phase II Study

Mediastinal Lymph Node Clearance after Docetaxel-Cisplatin Neoadjuvant Chemotherapy is Prognostic of Survival in Patients with Stage IIIA Pn2 Non-Small-cell Lung Cancer: a Multicenter Phase II Trial.

Consolidation chemotherapy improves progression-free survival in stage III small-cell lung cancer following concurrent chemoradiotherapy: a retrospective study.

Concomitant Chemoradiation Therapy Phase II Study Comparing Pemetrexed/Carboplatin with Paclitaxel/Carboplatin in Patients with Unresectable Stage III Non-small Cell Lung Cancer